Clinical trials
Adverse Event clinical trials
Below are recruiting adverse event clinical trials, each written for real people, not researchers. We’re tracking 180 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06117176Recruiting
Study of airway management during adult anesthesia (PAPAYA III)
This study watches how breathing tubes and masks are managed during anesthesia to improve safety. It is for any adult who needs airway help during a procedure, whether planned or emergency.
BerlinAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Duarte, CaliforniaAges 18 years+ - NCT06100744RecruitingPhase 3
Comparing two drugs for children with psoriatic arthritis
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Little Rock, ArkansasAges 5–17 - NCT06037811RecruitingPhase 2
Adalimumab for Immunotherapy-Related Arthritis
This study tests if a medicine called adalimumab (a type of TNF blocker) can help with new joint pain and swelling (inflammatory arthritis) caused by some immunotherapy drugs. It aims to reduce the need for high-dose steroids and improve symptoms.
London, OntarioAges 18 years+ - NCT06023030Recruiting
Observing how upadacitinib works for Crohn's disease in Japan
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
Anjo-shi, Aichi-kenAges 15 years+ - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 2–17 - NCT05908591Recruiting
Pregnancy sleep study on breathing, blood vessel function, and safety
This study looks at how sleep and breathing changes during pregnancy may affect blood vessel function and pregnancy safety. You may be asked about your sleep and possibly have health checks during the middle of pregnancy.
Edmonton, AlbertaAges 18 years+ - NCT05786274Recruiting
Predicting stroke risk after heart surgery using heart signals and MRI
This study looks at ways to predict harmful brain and blood-vessel side effects after heart surgery. It may help doctors identify higher-risk patients sooner so they can monitor them more closely.
San Donato Milanese, MilanAges 18 years+ - NCT05711394RecruitingPhase 3
Atogepant for preventing episodic migraine in children
This study tests whether an oral medicine called atogepant can reduce migraine activity in children ages 6–17 and checks its side effects. It’s meant for kids with episodic migraine (not the more constant types) who may benefit from preventive treatment.
Huntsville, AlabamaAges 6–17 - NCT05707949Enrolling by invitationPhase 3
Long-term safety study of atogepant for kids with migraine
This trial studies the long-term safety (side effects over time) of atogepant tablets in children and teens with migraine. It may help families understand whether the medicine is safe for longer use in ages 6 to 17.
Huntsville, AlabamaAges 6–17 - NCT05650632RecruitingPhase 1
IV infusion safety study of etentamig for multiple myeloma
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
Phoenix, ArizonaAges 18 years+ - NCT05609630RecruitingPhase 3
Testing two medicines for active systemic juvenile arthritis
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Phoenix, ArizonaAges 1–17 - NCT05158894Recruiting
Pregnancy safety registry for migraine medicines Ubrelvy and Qulipta
This is an observational study (no treatment is assigned) that tracks side effects and pregnancy outcomes in people taking Ubrelvy or Qulipta for migraine during pregnancy. It may help doctors better understand how these medicines affect mothers and babies.
Durham, North CarolinaAges 18 years+ - NCT05407129Recruiting
Improve hospital safety by sharing your recent experience
This trial asks patients, families, caregivers, and hospital staff to report what happened during a recent hospital stay to help improve safety. Your feedback may help the hospital change processes that prevent problems for others.
Boston, MassachusettsAges Any age - NCT05345821Recruiting
Study of side effects and satisfaction after silicone breast implants
This trial follows women who get their first breast implant surgery or a repeat (primary vs secondary) and records side effects and how satisfied they feel. It aims to better understand safety and satisfaction with smooth-surface silicone implants.
Santo André, São PauloAges 18 years+ - NCT05139706Recruiting
Study immune side effects after cancer immunotherapy
This study looks at how immune-related side effects happen in people treated with certain cancer immunotherapies. It also includes some healthy volunteers and people who already have similar autoimmune conditions, to better understand and compare these reactions.
Montreal, QuebecAges 18–100 - NCT05125302RecruitingPhase 3
Ubrogepant for acute migraine relief in kids and teens
This study tests how safe ubrogepant is and whether it helps treat an individual migraine attack in children and teens. It focuses on measuring side effects and whether headaches improve 2 hours after taking the study medicine.
Huntsville, AlabamaAges 6–17 - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT04928846RecruitingPhase 3
Telisotuzumab vedotin vs docetaxel for advanced non-squamous lung cancer
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
Birmingham, AlabamaAges 18 years+ - NCT04895436RecruitingPhase 2
Oral venetoclax plus IV obinutuzumab after prior CLL treatment
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
La Jolla, CaliforniaAges 18 years+ - NCT04824066Recruiting
Using wearables to spot complications early
This study checks whether common wearable devices can predict or detect problems after treatment or surgery. If you join, the researchers will compare what the wearable shows with what happens to you medically, to see if earlier warnings are possible.
Boston, MassachusettsAges 18 years+ - NCT04777357RecruitingPhase 3
Cariprazine for bipolar depression in ages 10 to 17
This Phase 3 study tests whether cariprazine can improve depression symptoms in children and teens with bipolar I disorder, and also tracks side effects. It may help if your depressive episode is ongoing and you meet specific mood and screening score requirements.
Bentonville, ArkansasAges 10–17 - NCT04682145Enrolling by invitation
Uses EUHASS data to study turoctocog alfa pegol side effects
This study collects and reviews side-effect information from the EUHASS registry in people with hemophilia. It may help doctors better understand how turoctocog alfa pegol (a clotting medicine) is tolerated in real-world care.
SøborgAges Any age - NCT04419480Recruiting
Monitoring to help prevent complications after cardiogenic shock
This study tests a special monitoring approach (likely using an implanted device) to help prevent serious complications after you survive cardiogenic shock in the hospital. It may help the care team detect problems earlier so treatments can start sooner.
Falls Church, VirginiaAges 18 years+
Hear when a new Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse event?
- Yes. Clin2 currently lists 180 recruiting adverse event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.